Biopharmaceutical Co. Raises $250M From RTW Investments
Law360 (July 14, 2020, 5:03 PM EDT) -- Biopharmaceutical company Cytokinetics said Tuesday it's entered a series of deals with funds backed by RTW Investments to raise $250 million and that have the potential to bring in an additional $200 million for its work involving heart disease drug candidates.
South San Francisco, California-based Cytokinetics Inc. agreed to the deals with funds and entities managed by New York-based RTW Investments LP that largely involve a drug candidate meant to treat hypertrophic cardiomyopathies, which involve the thickening of heart muscles, according to its statement and a filing with the U.S. Securities and Exchange Commission.
"These deals afford us the opportunity to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!